In conclusion, the development of oral, potent, small molecule and mutant specific IDH1 and IDH2 inhibitors represents an early success story of the cancer genome-sequencing era, and signifies an important advance for AML therapy in the era of personalized therapeutics. Here, IDH2 is linked to cancer.